Genome Editing in Drug Discovery

55 Mou, H., Smith, J.L., Peng, L. et al. (2017). CRISPR/Cas9‐mediated genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol. 18: 108.

56 Munoz, D.M., Cassiani, P.J., Li, L. et al. (2016). CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false‐positive hits for highly amplified genomic regions. Cancer Discov. 6: 900–913.

57 Najm, F.J., Strand, C., Donovan, K.F. et al. (2018). Orthologous CRISPR‐Cas9 enzymes for combinatorial genetic screens. Nat. Biotechnol. 36: 179–189.

58 Oughtred, R., Stark, C., Breitkreutz, B.J. et al. (2019). The BioGRID interaction database: 2019 update. Nucleic Acids Res. 47: D529–D541.

59 Pattanayak, V., Lin, S., Guilinger, J.P. et al. (2013). High‐throughput profiling of off‐target DNA cleavage reveals RNA‐programmed Cas9 nuclease specificity. Nat. Biotechnol. 31: 839–843.

60 Pichler, F.B. and Turner, S.J. (2007). The power and pitfalls of outsourcing. Nat. Biotechnol. 25: 1093–1096.

61 Popp, M.W. and Maquat, L.E. (2016). Leveraging rules of nonsense‐mediated mRNA decay for genome engineering and personalized medicine. Cell 165: 1319–1322.

62 Qiu, P., Shandilya, H., D'alessio, J.M. et al. (2004). Mutation detection using Surveyor nuclease. BioTechniques 36: 702–707.

63 Ran, F.A., Cong, L., Yan, W.X. et al. (2015). in vivo genome editing using Staphylococcus aureus Cas9. Nature 520: 186–191.

64 Rosenbluh, J., Xu, H., Harrington, W. et al. (2017). Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat. Commun. 8: 15403.

65 Safari, F., Zare, K., Negahdaripour, M. et al. (2019). CRISPR Cpf1 proteins: structure, function and implications for genome editing. Cell Biosci. 9: 36.

66 Sanson, K.R., Hanna, R.E., Hegde, M. et al. (2018). Optimized libraries for CRISPR‐Cas9 genetic screens with multiple modalities. Nat. Commun. 9: 5416.

67 Sanson, K.R., Deweirdt, P.C., Sangree, A.K. et al. (2020). Optimization of AsCas12a for combinatorial genetic screens in human cells. bioRxiv https://www.biorxiv.org/content/10.1101/747170v1.

68 Seki, A. and Rutz, S. (2018). Optimized RNP transfection for highly efficient CRISPR/Cas9‐mediated gene knockout in primary T cells. J. Exp. Med. 215: 985–997.

69 Sharpe, J.J. and Cooper, T.A. (2017). Unexpected consequences: exon skipping caused by CRISPR‐generated mutations. Genome Biol. 18: 109.

70 Shifrut, E., Carnevale, J., Tobin, V. et al. (2018). Genome‐wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175: 1958–1971. e15.

71 Slaymaker, I.M., Gao, L., Zetsche, B. et al. (2016). Rationally engineered Cas9 nucleases with improved specificity. Science 351: 84–88.

72 Smits, A.H., Ziebell, F., Joberty, G. et al. (2019). Biological plasticity rescues target activity in CRISPR knock outs. Nat. Methods 16: 1087–1093.

73 Song, C.Q., Li, Y., Mou, H. et al. (2017). Genome‐wide CRISPR screen identifies regulators of mitogen‐activated protein kinase as suppressors of liver tumors in mice. Gastroenterology 152: 1161–1173. e1.

74 Strezoska, Z., Perkett, M.R., Chou, E.T. et al. (2017). High‐content analysis screening for cell cycle regulators using arrayed synthetic crRNA libraries. J. Biotechnol. 251: 189–200.

75 Tak, Y.E., Kleinstiver, B.P., Nunez, J.K. et al. (2017). Inducible and multiplex gene regulation using CRISPR‐Cpf1‐based transcription factors. Nat. Methods 14: 1163–1166.

76 Takeda, H., Kataoka, S., Nakayama, M. et al. (2019). CRISPR‐Cas9‐mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc. Natl. Acad. Sci. U. S. A. 116: 15635–15644.

77 Thomas, J.D., Polaski, J.T., Feng, Q. et al. (2020). RNA isoform screens uncover the essentiality and tumor‐suppressor activity of ultraconserved poison exons. Nat. Genet. 52: 84–94.

78 Tuladhar, R., Yeu, Y., Tyler Piazza, J. et al. (2019). CRISPR‐Cas9‐based mutagenesis frequently provokes on‐target mRNA misregulation. Nat. Commun. 10: 4056.

79 Tzelepis, K., Koike‐Yusa, H., De Braekeleer, E. et al. (2016). A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in Acute Myeloid Leukemia. Cell Rep. 17: 1193–1205.

80 Vakulskas, C.A., Dever, D.P., Rettig, G.R. et al. (2018). A high‐fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24: 1216–1224.

81 Van Der Meer, D., Barthorpe, S., Yang, W. et al. (2019). Cell Model Passports‐a hub for clinical, genetic and functional datasets of preclinical cancer models. Nucleic Acids Res. 47: D923–D929.

82 Wang, T., Birsoy, K., Hughes, N.W. et al. (2015). Identification and characterization of essential genes in the human genome. Science 350: 1096–1101.

83 Wei, J., Long, L., Zheng, W. et al. (2019). Targeting REGNASE‐1 programs long‐lived effector T cells for cancer therapy. Nature 576: 471–476.

84 Wienert, B., Wyman, S.K., Richardson, C.D. et al. (2019). Unbiased detection of CRISPR off‐targets in vivo using DISCOVER‐Seq. Science 364: 286–289.

85 Wiszniewska, J., Bi, W., Shaw, C. et al. (2014). Combined array CGH plus SNP genome analyses in a single assay for optimized clinical testing. Eur. J. Hum. Genet. 22: 79–87.

86 Wu, J. and Yin, H. (2019). Engineering guide RNA to reduce the off‐target effects of CRISPR. J. Genet. Genomics 46: 523–529.

87 Yau, E.H., Kummetha, I.R., Lichinchi, G. et al. (2017). Genome‐wide CRISPR screen for essential cell growth mediators in mutant KRAS colorectal cancers. Cancer Res. 77: 6330–6339.

88 Ye, L., Park, J.J., Dong, M.B. et al. (2019). in vivo CRISPR screening in CD8 T cells with AAV‐sleeping beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat. Biotechnol. 37: 1302–1313.

89 Yeung, A.T.Y., Choi, Y.H., Lee, A.H.Y. et al. (2019). A genome‐wide knockout screen in human macrophages identified host factors modulating salmonella infection. MBio 10.

90 Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O. et al. (2015). Cpf1 is a single RNA‐guided endonuclease of a class 2 CRISPR‐Cas system. Cell 163: 759–771.

91 Zhang, F. (2019). Development of CRISPR‐Cas systems for genome editing and beyond. Q. Rev. Biophys. 52: 1–31.

92 Zhao, Y., Tyrishkin, K., Sjaarda, C. et al. (2019). A one‐step tRNA‐CRISPR system for genome‐wide genetic interaction mapping in mammalian cells. Sci. Rep. 9: 14499.

93 Zischewski, J., Fischer, R., and Bortesi, L. (2017). Detection of on‐target and off‐target mutations generated by CRISPR/Cas9 and other sequence‐specific nucleases. Biotechnol. Adv. 35: 95–104.

Текст предоставлен ООО «ЛитРес».

Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.

Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.